Welcome to our dedicated page for PAVmed news (Ticker: PAVM), a resource for investors and traders seeking the latest updates and insights on PAVmed stock.
PAVmed Inc. (Nasdaq: PAVM) is a cutting-edge medical device company focused on bringing innovative medical technologies from concept to commercialization with exceptional speed and efficiency. Headquartered in New York, PAVmed is led by three seasoned medical device entrepreneurs. The company is structured to develop and commercialize a diversified pipeline of breakthrough products that address unmet clinical needs, thereby enhancing and accelerating value creation through a business model centered on capital and time efficiency.
PAVmed operates in a single segment as a medical technology company, with three primary lines of business: Diagnostics, Medical Devices, and Digital Health. Through its majority-owned subsidiary, Lucid Diagnostics Inc. (Nasdaq: LUCD), the company offers products such as the EsoGuard Esophageal DNA Test and the EsoCheck Esophageal Cell Collection Device. These tools are designed for the early detection of esophageal precancer, aiming to prevent esophageal cancer by identifying at-risk patients early.
Another significant subsidiary is Veris Health Inc., which focuses on enhanced personalized cancer care through remote patient monitoring. Veris is developing an innovative implantable physiological monitor that interfaces with the Veris Cancer Care Platform, providing real-time health data to improve patient outcomes.
Recent notable achievements include a partnership between Lucid Diagnostics and the Esophageal Cancer Action Network (ECAN) to promote Esophageal Cancer Awareness Month, highlighting the critical link between chronic heartburn and esophageal cancer. Additionally, Lucid has published positive data from a National Cancer Institute-sponsored clinical validation study, which demonstrated EsoGuard's unprecedented early detection capabilities for esophageal precancer compared to traditional endoscopic methods.
PAVmed's commitment to innovation is further exemplified by its business updates and financial results discussions, providing shareholders and potential investors with transparent insights into the company's operational progress and strategic direction. The company's diversified approach in the medical technology sector positions it as a significant player in advancing healthcare and improving patient outcomes.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) recently announced that its subsidiary, Lucid Diagnostics Inc., has filed a Form S-1 registration with the SEC for a proposed initial public offering of its common stock. The offering details, including the number of shares and price range, are yet to be determined. Lucid intends to list on Nasdaq under the ticker 'LUCD.' Cantor Fitzgerald & Co. and Canaccord Genuity LLC will manage the offering, with BTIG, LLC and Needham & Co., LLC as co-managers. This offering aims to bolster Lucid’s market presence and product development.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that its subsidiary Veris Health Inc. has joined Microsoft for Startups, gaining access to advanced technology and support to expedite its remote digital healthcare platform focused on cancer care. Veris is collaborating with Loka Inc. for platform development on Microsoft Azure, integrating AI and IoT for better patient monitoring. Veris aims for FDA clearance of its intelligent implantable vascular access port by H2-2022, enhancing data-driven patient care and optimizing treatment outcomes.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has announced its participation in three prominent conferences: the
PAVmed reported a business update highlighting progress in its subsidiary, Lucid Diagnostics, for Q2 2021. Lucid conducted 202 EsoGuard tests, a 110% increase sequentially, and partnered with UpScriptHealth for telemedicine support. Lucid also received CE Mark certification for its EsoCheck and EsoGuard devices, enhancing marketability in Europe. Financially, PAVmed incurred a GAAP net loss of approximately $11.5 million, or $(0.14) per share, while cash reserves increased to $43.2 million. The company's strategic initiatives aim for long-term growth and shareholder value enhancement.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced the launch of three Lucid Test Centers in Phoenix for testing patients with gastroesophageal reflux disease (GERD). This initiative aims to enhance EsoGuard commercialization and target primary care physicians (PCPs) for early detection of esophageal precancer. The centers utilize the EsoCheck device for a rapid, non-invasive procedure. A single nurse practitioner can conduct up to twenty tests daily. Lucid plans to expand the program across Western U.S. states, operating modestly with fixed costs and margins.
PAVmed (Nasdaq: PAVM, PAVMZ) announced that Dr. Lishan Aklog, Chairman and CEO, will present a corporate update at the 41st Annual Canaccord Genuity Growth Conference on August 11, 2021, at 5:00 PM EDT. Investors can access the live webcast here. A replay will be available on the PAVmed website.
PAVmed focuses on innovative medical technologies, with products for early detection of esophageal cancer and minimally invasive interventions.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced that Aster Angagaw has joined the Board of Directors of its subsidiary, Lucid Diagnostics. Angagaw brings extensive experience in healthcare and business transformation, previously serving prominent roles at Owens & Minor and ServiceMaster Brands. PAVmed's chairman, Lishan Aklog, emphasized her expertise will enhance Lucid's growth strategy in precancer screening technologies. This appointment is expected to strengthen Lucid's leadership as it aims for long-term expansion.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) announced a business update conference call scheduled for August 12, 2021, at 4:30 PM EDT. CEO Lishan Aklog will discuss near-term milestones and the growth strategy, while CFO Dennis McGrath will present the second quarter 2021 financial results. Interested parties can join by phone or via webcast on the company’s website. PAVmed focuses on developing differentiated medical technologies, addressing unmet needs across several clinical areas, with subsidiaries such as Lucid Diagnostics and Veris Health.
PAVmed Inc. (Nasdaq: PAVM, PAVMZ) has appointed medical diagnostics pioneer Stanley N. Lapidus as Vice Chairman of its subsidiary, Lucid Diagnostics Inc. Lapidus, a former CEO of Exact Sciences, is known for his contributions to early cancer detection technologies. He aims to promote the EsoGuard test for early detection of esophageal cancer. PAVmed's management highlights Lapidus’s strategic input in ongoing initiatives, reinforcing Lucid's long-term growth plans. PAVmed continues to innovate with a broad product pipeline targeting unmet clinical needs.
FAQ
What is the current stock price of PAVmed (PAVM)?
What is the market cap of PAVmed (PAVM)?
What does PAVmed Inc. do?
What are PAVmed's main products?
What is EsoGuard?
Who leads PAVmed Inc.?
What recent achievements has PAVmed made?
What is Veris Health?
How does PAVmed enhance value creation?
What areas does PAVmed operate in?
How can I access PAVmed's latest updates?
Where can I find more information about PAVmed?
